Dual blockade of angiotensin-II and aldosterone suppresses the progression of a non-diabetic rat model of steatohepatitis

Hepatology Research

Volumn 43, Issue 7, 2013, Pages 765-774

  Noguchi, Ryuichi ^a   Yoshiji, Hitoshi ^a   Ikenaka, Yasuhide ^a   Kaji, Kosuke ^a   Aihara, Yosuke ^a   Shirai, Yusaku ^a   Namisaki, Tadashi ^a   Kitade, Mitsuteru ^a   Douhara, Akitoshi ^a   Moriya, Kei ^a   Fukui, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Aldosterone; Angiogenesis; Angiotensin II; Hepatocarcinogenesis; Liver fibrosis; Selective aldosterone blocker

Indexed keywords

ALDOSTERONE ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUTATHIONE TRANSFERASE; SELECTIVE ALDOSTERONE BLOCKING AGENT; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; DISEASE COURSE; IN VITRO STUDY; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER FIBROSIS; MALE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; RAT; STELLATE CELL;

EID: 84879728216     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12008     Document Type: Article

References (51)

1. Yoshiji H, Yoshii J, Ikenaka Y etal. Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. J Hepatol 2002; 37: 22-30.
2. Yoshiji H, Kuriyama S, Fukui H. Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol 2002; 23: 348-356.
3. Yoshiji H, Kuriyama S, Noguchi R etal. Amelioration of carcinogenesis and tumor growth in the rat liver by combination of vitamin K2 and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. Oncol Rep 2006; 15: 155-159.
4. Hirose A, Ono M, Saibara T etal. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 2007; 45: 1375-1381.
5. Tox U, Steffen HM. Impact of inhibitors of the Renin-Angiotensin-aldosterone system on liver fibrosis and portal hypertension. Curr Med Chem 2006; 13: 3649-3661.
6. Noguchi R, Yoshiji H, Ikenaka Y etal. Selective aldosterone blocker ameliorates the progression of non-alcoholic steatohepatitis in rats. Int J Mol Med 2010; 26: 407-413.
7. Kaji K, Yoshiji H, Kitade M etal. Selective aldosterone blocker, eplerenone, attenuates hepatocellular carcinoma growth and angiogenesis in mice. Hepatol Res 2010; 40: 540-549.
8. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A etal. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A 2003; 100: 14211-14216.
9. Vleugels K, Schinner S, Krause D etal. ERK1/2 MAPKs and Wnt signaling pathways are independently involved in adipocytokine-mediated aldosterone secretion. Exp Clin Endocrinol Diabetes 2011; 119: 644-648.
10. Nguyen Dinh Cat A, Jaisser F. Extrarenal effects of aldosterone. Curr Opin Nephrol Hypertens 2012; 21: 147-156.
11. Habibi J, DeMarco VG, Ma L etal. Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression. Am J Physiol Heart Circ Physiol 2011; 300: H1484-1491.
12. Yokohama S, Yoneda M, Haneda M etal. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004; 40: 1222-1225.
13. Pitt B, Zannad F, Remme WJ etal. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
14. Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008; 118: 1643-1650.
15. Yoshiji H, Kuriyama S, Kawata M etal. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 2001; 7: 1073-1078.
16. Kobayashi N, Hara K, Tojo A etal. Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway. Hypertension 2005; 45: 538-544.
17. Yoshiji H, Kuriyama S, Yoshii J etal. The copper-chelating agent, trientine, attenuates liver enzyme-altered preneoplastic lesions in rats by angiogenesis suppression. Oncol Rep 2003; 10: 1369-1373.
18. Noguchi R, Yoshiji H, Ikenaka Y etal. Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities. Oncol Rep 2009; 22: 355-360.
19. Yoshiji H, Kuriyama S, Yoshii J etal. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001; 34: 745-750.
20. Weiskirchen R, Gressner AM. Isolation and culture of hepatic stellate cells. Methods Mol Med 2005; 117: 99-113.
21. Rockey DC, Boyles JK, Gabbiani G, Friedman SL. Rat hepatic lipocytes express smooth muscle actin upon activation in vivo and in culture. J Submicrosc Cytol Pathol 1992; 24: 193-203.
22. Yoshiji H, Kuriyama S, Yoshii J etal. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology 2002; 35: 834-842.
23. Yoshiji H, Kuriyama S, Noguchi R etal. Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression. J Hepatol 2005; 42: 687-693.
24. Nakae D, Yoshiji H, Mizumoto Y etal. High incidence of hepatocellular carcinomas induced by a choline deficient L-amino acid defined diet in rats. Cancer Res 1992; 52: 5042-5045.
25. Kaji K, Yoshiji H, Kitade M etal. Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats. Am J Physiol Gastrointest Liver Physiol 2011; 300: G1094-1104.
26. Bjornsson E. The clinical aspects of non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol 2008; 54: 7-18.
27. Yoshiji H, Noguchi R, Ikenaka Y etal. Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: a randomized control trial. Oncol Rep 2011; 26: 1547-1553.
28. Yoshiji H, Noguchi R, Ikenaka Y etal. Combination of branched-chain amino acid and angiotensin-converting enzyme inhibitor improves liver fibrosis progression in patients with cirrhosis. Mol Med Report 2012; 5: 539-544.
29. Nobakht N, Kamgar M, Rastogi A, Schrier RW. Limitations of angiotensin inhibition. Nat Rev Nephrol 2011; 7: 356-359.
30. Onozato ML, Tojo A, Kobayashi N, Goto A, Matsuoka H, Fujita T. Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney. Nephrol Dial Transplant 2007; 22: 1314-1322.
31. Imanishi T, Ikejima H, Tsujioka H etal. Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability. Hypertension 2008; 51: 734-741.
32. Nishiyama A, Kobori H, Konishi Y etal. Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats. J Pharmacol Exp Ther 2009; 332: 1072-1080.
33. Liang W, Chen C, Shi J etal. Disparate effects of eplerenone, amlodipine and telmisartan on podocyte injury in aldosterone-infused rats. Nephrol Dial Transplant 2011; 26: 789-799.
34. Montezano AC, Callera GE, Yogi A etal. Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. Arterioscler Thromb Vasc Biol 2008; 28: 1511-1518.
35. Paternostro C, David E, Novo E, Parola M. Hypoxia, angiogenesis and liver fibrogenesis in the progression of chronic liver diseases. World J Gastroenterol 2010; 16: 281-288.
36. Valfre di Bonzo L, Novo E, Cannito S etal. Angiogenesis and liver fibrogenesis. Histol Histopathol 2009; 24: 1323-1341.
37. Yoshiji H, Kuriyama S, Yoshii J etal. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 2003; 52: 1347-1354.
38. Kitade M, Yoshiji H, Kojima H etal. Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. Hepatology 2006; 44: 983-991.
39. Amarapurkar AD, Amarapurkar DN, Vibhav S, Patel ND. Angiogenesis in chronic liver disease. Ann Hepatol 2007; 6: 170-173.
40. Ueno T, Nakamura T, Torimura T, Sata M. Angiogenic cell therapy for hepatic fibrosis. Med Mol Morphol 2006; 39: 16-21.
41. Yoshiji H, Kuriyama S, Yoshii J etal. Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. Hepatology 2004; 39: 1517-1524.
42. Yoshiji H, Kuriyama S, Yoshii J etal. Involvement of the vascular endothelial growth factor receptor-1 in murine hepatocellular carcinoma development. J Hepatol 2004; 41: 97-103.
43. Yoshiji H, Kuriyama S, Hicklin DJ etal. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells. Hepatology 1999; 30: 1179-1186.
44. Noguchi R, Yoshiji H, Ikenaka Y etal. Different tumoricidal effects of interferon subclasses and p53 status on hepatocellular carcinoma development and neovascularization. Int J Oncol 2008; 32: 193-199.
45. Yoshiji H, Kuriyama S, Noguchi R, Fukui H. Angiotensin-I converting enzyme inhibitors as potential anti-angiogenic agents for cancer therapy. Curr Cancer Drug Targets 2004; 4: 555-567.
46. Li CY, Shan S, Huang Q etal. Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst 2000; 92: 143-147.
47. Frachon S, Gouysse G, Dumortier J etal. Endothelial cell marker expression in dysplastic lesions of the liver: an immunohistochemical study. J Hepatol 2001; 34: 850-857.
48. Taye A, Raheem A. Hepatoprotective effect of the selective mineralocorticoid receptor antagonist, eplerenone against carbon tetrachloride-induced liver injury in rats. Ann Hepatol 2012; 11: 384-391.
49. Saruta T, Kageyama S, Ogihara T etal. Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study. J Clin Hypertens 2004; 6: 175-183.
50. Rautureau Y, Paradis P, Schiffrin EL. Cross-talk between aldosterone and angiotensin signaling in vascular smooth muscle cells. Steroids 2011; 76: 834-839.
51. Noda K, Kobara M, Hamada J etal. Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and Angiotensin receptor blockers in postinfarct failing hearts. J Cardiovasc Pharmacol 2012; 60: 140-149.